Novartis agrees to acquire Excellergy for up to $2 billion to boost immunology pipeline and expand US presence
Novartis has announced plans to acquire US-based biotech firm Excellergy in a deal valued at up to $2 billion, marking its second major acquisition in as many weeks.
The Swiss drugmaker said the agreement includes upfront and milestone payments that could total $2 billion. The transaction is expected to close in the second half of 2026, subject to customary conditions, including regulatory approvals.
Novartis said the acquisition will strengthen its position in immunology, particularly in the food allergy treatment market. Excellergy’s lead drug candidate, Exl-111, is designed to provide earlier relief from allergy symptoms, positioning it as a potential addition to Novartis’ expanding pipeline.
The deal follows another significant move by Novartis last week, when it agreed to acquire a breast cancer drug candidate for up to $3 billion from US-based Synnovation Therapeutics, underscoring a broader strategy to deepen its portfolio through targeted acquisitions.
Beyond acquisitions, Novartis has also been ramping up its investment footprint in the United States. In April last year, the company announced plans to invest $23 billion over five years to build and expand research, development, and manufacturing facilities across the country.